FrancophonIA/ELRC3.0 huggingface dataset:
English: o Additional bolus for PCI when last SC administration was given more than 8 hours before balloon inflation For patients being managed with PCI, an additional IV bolus of 30 IU/kg (0.3 mg/kg) is to be administered if last SC administration was given more than 8 hours before balloon inflation.
Slovenian: o Dodaten bolus za PKI, če je bil zadnji subkutani odmerek uporabljen več kot 8 ur pred balonskim širjenjem Bolniki, zdravljeni s PKI, morajo dobiti dodaten intravenski odmerek 30 i.e./kg (0,3 mg/kg), če je bil zadnji subkutani odmerek uporabljen več kot 8 ur pred balonskim širjenjem.
English: Method of administration Inhixa should not be administered by the intramuscular route.
Slovenian: Način uporabe Zdravila Inhixa se ne sme injicirati intramuskularno.
English: In the clinical studies for treatment of unstable angina and non-Q-wave myocardial infarction, doses were 100 IU/kg (1 mg/kg) subcutaneously every 12 hours, and in the clinical study for treatment of acute STEMI enoxaparin sodium regimen was a 3,000 IU (30 mg) intravenous bolus followed by 100 IU/kg (1 mg/kg) subcutaneously every 12 hours.
Slovenian: V kliničnih študijah za zdravljenje nestabilne angine pektoris in miokardnega infarkta brez zobca Q so bili odmerki 100 i.e./kg (1 mg/kg) subkutano na 12 ur, v klinični študij za zdravljenje akutnega STEMI pa je bila shema natrijevega enoksaparinata 3.000 i.e. (30 mg) v intravenskem bolusu, ki mu je sledila uporaba 100 i.e./kg (1 mg/kg) subkutano na 12 ur.
English: If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Slovenian: Če ste noseči, domnevate, da ste noseči ali nameravate zanositi, se posvetujte z zdravnikom, preden uporabite to zdravilo.
English: Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection Inhixa 15,000 IU (150 mg)/1 mL solution for injection enoxaparin sodium
Slovenian: Inhixa 12.000 i.e. (120 mg)/0,8 ml raztopina za injiciranje Inhixa 15.000 i.e. (150 mg)/1 mL raztopina za injiciranje natrijev enoksaparinat
English: Inhixa 12,000 IU (120 mg)/0.8 mL
Slovenian: Inhixa 12.000 i.e. (120 mg)/0,8 ml
English: Sodium content This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'.
Slovenian: Vsebnost natrija To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni »brez natrija«.
English: Inhixa 100,000 IU (1000 mg)/10 mL
Slovenian: Inhixa 100.000 i.e. (1000 mg)/10 ml
English: • Inhixa is added to the tube leaving the body (arterial line) at the start of the dialysis session.
Slovenian: • Zdravilo Inhixa se na začetku dialize da v cevko, ki vodi iz telesa (v arterijsko linijo).
English: Accidental overdose with enoxaparin sodium after intravenous, extracorporeal or subcutaneous administration may lead to haemorrhagic complications.
Slovenian: Naključno preveliko odmerjanje intravensko, izventelesno ali subkutano uporabljenega natrijevega enoksaparinata lahko povzroči krvavitvene zaplete.
English: All Treated DVT Patients with or without PE Total VTE (%)
Slovenian: Vsi zdravljeni bolniki z GVT, s PE ali brez nje Vse VTE (%) Samo GVT (%) Proksimalne GVT
English: A puncture-free interval of at least 24 hours shall be kept between the last injection of enoxaparin sodium at curative doses and the needle or catheter placement (see also section 4.3).
Slovenian: Med zadnjo injekcijo natrijevega enoksaparinata v kurativnih odmerkih in vstavitvijo igle ali katetra mora miniti vsaj 24 ur brez punkcij (glejte tudi poglavje 4.3).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Slovenian: PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH VEČODMERNE VIALE
English: How to give yourself an injection of Inhixa
Slovenian: Kako si sami injicirate zdravilo Inhixa
English: Inhixa 10,000 IU (100 mg)/1 mL
Slovenian: Inhixa 10.000 i.e. (100 mg)/1 ml
English: - Changing from treatment with direct oral anticoagulant to Inhixa Stop taking direct oral anticoagulant.
Slovenian: - Prehod z zdravljenja z neposrednim peroralnim antikoagulansom na zdravilo Inhixa Nehajte jemati neposredni peroralni antikoagulans.
English: 6 pre-filled syringes
Slovenian: 6 napolnjenih injekcijskih brizg
English: This medicine contains less than 1 mmol sodium (23 mg) per dose within the recommended dose range, that is to say essentially ‘sodium-free'.
Slovenian: To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, v priporočenem razponu odmerkov to v bistvu pomeni, da je »brez natrija«.
English: A 3,000 IU (30 mg) intravenous bolus immediately followed by a 100 IU/kg (1 mg/kg) subcutaneous every 12 hours provided initial maximum anti-Xa activity level of 1.16 IU/mL (n=16) and average exposure corresponding to 88% of steady-state levels.
Slovenian: Intravenski bolus 3.000 i.e. (30 mg), ki mu je takoj sledila subkutana uporaba 100 i.e./kg (1 mg/kg) na 12 ur, je dosegel uvodno največjo raven aktivnosti anti-Xa 1,16 i.e./ml (n = 16) in povprečno izpostavljenost, ki je ustrezala 88 % tiste v stanju dinamičnega ravnovesja.
English: In clinical studies, haemorrhages, thrombocytopenia and thrombocytosis were the most commonly reported reactions (see sections 4.4 and “Description of selected adverse reactions” below).
Slovenian: V kliničnih študijah so bili najpogosteje zabeleženi neželeni učinki krvavitve, trombocitopenija in trombocitoza (glejte poglavje 4.4 in "Opis izbranih neželenih učinkov", spodaj).
English: Enoxaparin sodium 100 IU/kg (1 mg/kg) twice a day subcutaneously n (%)
Slovenian: Natrijev enoksaparinat 100 i.e./kg (1 mg/kg) dvakrat na dan subkutano n (%)
English: To avoid the possible mixture of enoxaparin sodium with other drugs, the intravenous access chosen should be flushed with a sufficient amount of sodium chloride or dextrose solution prior to and following the intravenous bolus administration of enoxaparin sodium to clear the port of drug.
Slovenian: Da boste preprečili možno mešanje natrijevega enoksaparinata z drugimi zdravili, morate intravenski dostop sprati z zadostno količino raztopine natrijevega klorida ali raztopine glukoze, in sicer pred dajanjem intravenskega bolusa natrijevega enoksaparinata in po njem, da boste nastavek očistili zdravila.
English: SC injection.
Slovenian: Raztopina za injiciranje.
English: Very common: Thrombocytosisβ Common:
Slovenian: Zelo pogosti: Trombocitozaβ Pogosti:
English: 50 pre-filled syringes
Slovenian: 50 napolnjenih injekcijskih brizg
English: 30 pre-filled syringes
Slovenian: 30 napolnjenih injekcijskih brizg
English: What Inhixa looks like and contents of the pack Inhixa 12,000 IU (120 mg)/0.8 mL is 0.8 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a purple polypropylene plunger rod.
Slovenian: Izgled zdravila Inhixa in vsebina pakiranja 12.000 i.e. (120 mg)/0,8 ml je 0,8 ml raztopine v: - injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in z vijoličnim polipropilenskim batom.
English: • if you have any sign of blockage of a blood vessel by a blood clot such as: o cramping pain, redness, warmth, or swelling in one of your legs - these are symptoms of deep vein thrombosis o breathlessness, chest pain, fainting or coughing up blood - these are symptoms of a pulmonary embolism
Slovenian: - če imate kakršen koli znak zamašitve žile s krvnim strdkom, na primer: o krčevite bolečine, pordelost, toploto ali oteklost ene noge - to so simptomi globoke venske tromboze, o težko dihanje, bolečino v prsih, omedlevico ali izkašljevanje krvi - to so simptomi pljučne embolije, - če imate boleč izpuščaj s temno rdečimi podkožnimi pegami, ki ne izginejo, če nanje pritisnete.
English: Solution for injection 2 pre-filled syringes 10 pre-filled syringes 30 pre-filled syringes 10 pre-filled syringes with needle guard 30 pre-filled syringes with needle guard
Slovenian: 10 napolnjenih injekcijskih brizg 30 napolnjenih injekcijskih brizg 10 napolnjenih injekcijskih brizg z varnostno zaščito za iglo 30 napolnjenih injekcijskih brizg z varnostno zaščito za iglo
English: Changing from Inhixa to treatment with direct oral anticoagulant Stop using Inhixa.
Slovenian: - Prehod z zdravila Inhixa na zdravljenje z neposrednim peroralnim antikoagulansom Nehajte uporabljati zdravilo Inhixa.
English: One vial (5 mL) contains 50,000 IU (500 mg) enoxaparin sodium.
Slovenian: Ena viala (5 ml) vsebuje 50.000 i.e. (500 mg) natrijevega enoksaparinata.
English: Inhixa 50,000 IU (500 mg)/5 mL solution for injection in multidose vial
Slovenian: Inhixa 50.000 i.e. (500 mg)/ 5 ml raztopina za injiciranje v večodmerni viali
English: Mechanical prosthetic heart valves
Slovenian: Mehanične protetične srčne zaklopke
English: Enoxaparin sodium was found to have no effect on fertility or reproductive performance of male and female rats at subcutaneous doses up to 20 mg/kg/day.
Slovenian: Ugotovljeno je bilo, da natrijev enoksaparinat v subkutanih odmerkih do 20 mg/kg/dan ne vpliva na plodnost ali sposobnost razmnoževanja podganjih samcev in samic.
English: One vial (5.0 mL) contains 50,000 IU (500 mg) enoxaparin sodium.
Slovenian: Ena viala (5,0 ml) vsebuje 50.000 i.e. (500 mg) natrijevega enoksaparinata.
English: The mean maximum anti-IIa activity level is observed approximately 3 to 4 hours following subcutaneous injection and reaches 0.13 IU/mL and 0.19 IU/mL following repeated administration of 100 IU/kg (1 mg/kg) twice daily and 150 IU/kg (1.5 mg/kg) once daily, respectively.
Slovenian: Povprečna največja raven aktivnosti anti-IIa se pojavi približno 3 do 4 ure po subkutanem injiciranju in doseže po večkratni uporabi 100 i.e./kg (1 mg/kg) dvakrat na dan 0,13 i.e./ml in po uporabi 150 i.e./kg (1,5 mg/kg) enkrat na dan 0,19 i.e./ml.
English: One vial contains enoxaparin sodium 50,000 IU anti-Xa activity (equivalent to 500 mg) in 5.0 mL water for injections.
Slovenian: Ena viala vsebuje 50.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 500 mg) v 5,0 ml vode za injekcije.
English: Skin and subcutaneous tissue disorders o Common: Urticaria, pruritus, erythema o Uncommon: Bullous dermatitis o Rare: Alopecia* o Rare: Cutaneous vasculitis*, skin necrosis* usually occurring at the injection site (these phenomena have been usually preceded by purpura or erythematous plaques, infiltrated and painful).
Slovenian: • Redki: Alopecija* o Redki: Kožni vaskulitis*, nekroza kože*, ki se po navadi pojavi na mestu injiciranja (pred temi pojavi so se po navadi razvili purpura ali infiltrirani in boleči eritematozni plaki).
English: Volume to be injected through intravenous line after dilution is completed at a concentration of 300 IU (3 mg)/mL.
Slovenian: Količina, ki jo je treba injicirati v intravensko linijo po dokončanem razredčenju na koncentracijo 300 i.e. (3 mg)/ml.
English: • Other medicinal products affecting haemostasis such as: - Platelet aggregation inhibitors including acetylsalicylic acid used at antiaggregant dose (cardioprotection), clopidogrel, ticlopidine, and glycoprotein IIb/IIIa antagonists indicated in acute coronary syndrome due to the risk of bleeding, - Dextran 40, - Systemic glucocorticoids.
Slovenian: • Druga zdravila, ki vplivajo na hemostazo, na primer: - zaviralci agregacije trombocitov, vključno z acetilsalicilno kislino v antiagregacijskih odmerkih (zaščita srca), klopidogrel, tiklopidin in antagonisti glikoproteina IIb/IIIa, ki so indicirani pri akutnem koronarnem sindromu, zaradi tveganja za krvavitve, - dekstran 40, - sistemski glukokortikoidi.
English: Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial
Slovenian: Inhixa 30.000 i.e. (300 mg)/3 ml raztopina za injiciranje v večodmerni viali
English: The mean maximum plasma anti-Xa activity level is observed 3 to 5 hours after subcutaneous injection and achieves approximately 0.2, 0.4, 1.0 and 1.3 anti-Xa IU/mL following single subcutaneous administration of 2,000 IU, 4,000 IU, 100 IU/kg and 150 IU/kg (20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg) doses, respectively.
Slovenian: Povprečna največja aktivnost anti-Xa v plazmi se pojavi od 3 do 5 ur po subkutanem injiciranju in doseže po enkratni subkutani uporabi 2.000 i.e. (20 mg) približno 0,2 anti-Xa i.e./ml, po 4.000 i.e. (40 mg) približno 0,4 anti-Xa i.e./ml, po 100 i.e./kg (1 mg/kg) približno 1,0 anti-Xa i.e./ml in po 150 i.e./kg (1,5 mg/kg) približno 1,3 anti-Xa i.e./ml.
English: Inhixa 15,000 IU (150 mg)/1 mL is 1 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a dark blue polypropylene plunger rod.
Slovenian: 15.000 i.e (150 mg)/1 ml je 1 ml raztopine v: injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in s temno modrim polipropilenskim batom.
English: One pre-filled syringe (0.8 mL) contains 12,000 IU (120 mg) enoxaparin sodium.
Slovenian: Ena napolnjena injekcijska brizga (0,8 ml) vsebuje 12.000 i.e. (120 mg) natrijevega enoksaparinata.
English: Diluted medicinal product with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose 8 hours
Slovenian: Zdravilo, razredčeno z raztopino natrijevega klorida 9 mg/ml (0,9%) za injiciranje ali 5 % glukozo 8 ur
English: CARTON (Packs of 1, 2, 6, 10, 20, 50 or 90)
Slovenian: ŠKATLA (pakiranja po 1, 2, 6, 10, 20, 50 ali 90)
English: Instructions on injecting yourself with Inhixa
Slovenian: NAVODILA ZA UPORABO: NAPOLNJENA INJEKCIJSKA BRIZGA Kako si injicirate zdravilo Inhixa
English: - Changing from blood thinners called vitamin-K antagonists (e.g. warfarin) to Inhixa Stop taking the vitamin-K antagonist.
Slovenian: - Prehod s sredstev za redčenje krvi, imenovanih antagonisti vitamina K (npr. varfarin) na zdravilo Inhixa
English: Enoxaparin sodium, as with any other anticoagulant therapy, should be used with caution in conditions with increased potential for bleeding, such as: - impaired haemostasis, - history of peptic ulcer, - recent ischemic stroke, - severe arterial hypertension, - recent diabetic retinopathy, - neuro- or ophthalmologic surgery, - concomitant use of medicinal products affecting haemostasis (see section 4.5).
Slovenian: Tako kot druge antikoagulanse je treba tudi natrijev enoksaparinat previdno uporabljati pri stanjih, povezanih z večjo možnostjo za krvavitve; takšna so npr.: - okvarjena hemostaza, - anamneza peptične razjede, - nedavna ishemična možganska kap, - huda arterijska hipertenzija, - nedavna diabetična retinopatija, - nevrološka ali oftalmološka operacija, - sočasna uporaba zdravil, ki poslabšajo hemostazo (glejte poglavje 4.5).
English: - Changing from Inhixa to treatment with direct oral anticoagulant Stop taking Inhixa.
Slovenian: - Prehod z zdravila Inhixa na zdravljenje z neposrednim peroralnim antikoagulansom Nehajte jemati zdravilo Inhixa.
English: Switch between enoxaparin sodium and direct oral anticoagulants (DOAC) For patients currently receiving enoxaparin sodium, discontinue enoxaparin sodium and start the DOAC 0 to 2 hours before the time that the next scheduled administration of enoxaparin sodium would be due as per DOAC label.
Slovenian: Bolnikom, ki trenutno prejemajo natrijev enoksaparinat, slednjega ukinite in uvedite DOAC od 0 do 2 uri pred časom, ko bi bil na vrsti naslednji redni odmerek natrijevega enoksaparinata (v skladu z navodili za uporabo DOAC).
English: Each pre-filled syringe contains enoxaparin sodium 15,000 IU anti-Xa activity (equivalent to 150 mg) in 1 mL water for injections.
Slovenian: Ena napolnjena injekcijska brizga vsebuje 15.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 150 mg) v 1 ml vode za injekcije.
English: Enoxaparin sodium 2,000 IU (20 mg) once a day subcutaneously n (%)
Slovenian: Natrijev enoksaparinat 2.000 i.e. (20 mg) enkrat na dan subkutano n (%)
English: Intracranial haemorrhage, Retroperitoneal haemorrhage α: such as haematoma, ecchymosis other than at injection site, wound haematoma, haematuria, epistaxis and gastro-intestinal haemorrhage.
Slovenian: Intrakranialna krvavitev, retroperitonealna krvavitev : npr. hematom, ekhimoze drugje kot na mestu injiciranja, hematom rane, hematurija, epistaksa in gastrointestinalna krvavitev.
English: VTE = venous thromboembolic event (DVT and/or PE) *The 95% Confidence Intervals for the treatment differences for total VTE were: - enoxaparin sodium once a day versus heparin (-3.0 to 3.5) - enoxaparin sodium every 12 hours versus heparin (-4.2 to 1.7).
Slovenian: VTE = venski trombembolični dogodek (GVT in/ali PE) *95-odstotna intervala zaupanja za razliko med zdravljenji za vse VTE sta bila: - natrijev enoksaparinat enkrat na dan v primerjavi s heparinom (-3,0 do 3,5) - natrijev enoksaparinat na 12 ur v primerjavi s heparinom (-4,2 do 1,7)
English: Inhixa 15,000 IU (150 mg)/1 mL solution for injection
Slovenian: Inhixa 15.000 i.e. (150 mg)/1 ml raztopina za injiciranje
English: Inhixa 100,000 IU (1000 mg)/10 mL solution for injection in multidose vial
Slovenian: Inhixa 100.000 i.e. (1000 mg)/10 ml raztopina za injiciranje v večodmerni viali
English: The air bubble should not be expelled from the syringe before the injection to avoid the loss of drug when using pre-filled syringes.
Slovenian: V primeru uporabe napolnjene injekcijske brizge iz nje pred injiciranjem ni priporočljivo odstraniti zračnega mehurčka, da ne pride do izgube zdravila.
English: SC injection Do not mix with other products.
Slovenian: Subkutano injiciranje Zdravila Inhixa ne smete mešati z drugimi zdravili.
English: Enoxaparin sodium, as with any other anticoagulant therapy, should be used with caution in conditions with increased potential for bleeding, such as: - impaired haemostasis, - history of peptic ulcer, - recent ischemic stroke, - severe arterial hypertension, recent diabetic retinopathy, - neuro- or ophthalmologic surgery, - concomitant use of medications affecting haemostasis (see section 4.5).
Slovenian: Tako kot druge antikoagulanse je treba tudi natrijev enoksaparinat previdno uporabljati pri stanjih, povezanih z večjo možnostjo za krvavitve; takšna so npr.: - okvarjena hemostaza, - anamneza peptične razjede, - nedavna ishemična možganska kap, - huda arterijska hipertenzija, - nedavna diabetična retinopatija, nevrološka ali oftalmološka operacija, - sočasna uporaba zdravil, ki poslabšajo hemostazo (glejte poglavje 4.5).
English: One vial contains enoxaparin sodium 30,000 IU anti-Xa activity (equivalent to 300 mg) in 3.0 mL water for injections.
Slovenian: Ena viala vsebuje 30.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 300 mg) v 3,0 ml vode za injekcije.
English: Volume to inject when diluted to a final concentration of 300 IU (3 mg)/mL
Slovenian: Količina, ki jo je treba injicirati, če je razredčenje opravljeno na končno koncentracijo 300 i.e. (3 mg) / ml
English: Common: Thrombocytopenia
Slovenian: Pogosti: Trombocitozaβ
English: One pre-filled syringe (1 mL) contains 15,000 IU (150 mg) enoxaparin sodium
Slovenian: Ena napolnjena injekcijska brizga (1 ml) vsebuje 15.000 i.e. (150 mg) natrijevega enoksaparinata
English: Treatment of acute ST-segment elevation myocardial infarction In a large multicentre study, 20,479 patients with STEMI eligible to receive fibrinolytic therapy were randomized to receive either enoxaparin sodium in a single 3,000 IU (30 mg) intravenous bolus plus a 100 IU/kg (1 mg/kg) subcutaneous dose followed by an subcutaneous injection of 100 IU/kg (1 mg/kg) every 12 hours or intravenous unfractionated heparin adjusted based on aPTT for 48 hours.
Slovenian: Zdravljenje akutnega miokardnega infarkta z dvigom spojnice ST V veliki multicentrični študiji so 20.479 bolnikov s STEMI, primernih za fibrinolitično zdravljenje, za 48 ur randomizirali ali na natrijev enoksaparinat v enkratnem intravenskem bolusu 3.000 i.e. (30 mg) ter 100 i.e./kg (1 mg/kg) subkutano, čemur je sledilo subkutano injiciranje 100 i.e./kg (1 mg/kg) na 12 ur ali na nefrakcionirani heparin intravensko glede na aPTČ.
English: One vial contains enoxaparin sodium 100,000 IU anti-Xa activity (equivalent to 1000 mg) in 10.0 mL water for injections.
Slovenian: Ena viala vsebuje 100.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 1000 mg) v 10,0 ml vode za injekcije.
English: Inhixa each day.
Slovenian: Inhixa na dan.
English: One vial (10.0 mL) contains 100,000 IU (1000 mg) enoxaparin sodium.
Slovenian: Ena viala (10,0 ml) vsebuje 100.000 i.e. (1000 mg) natrijevega enoksaparinata.
English: Pharmacotherapeutic group: Antithrombotic agents, heparin group.
Slovenian: 5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: antitrombotiki, heparinska skupina, oznaka ATC: B01A B05
English: Inhixa 4,000 IU (40 mg)/0.4 mL is 0.4 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a yellow polypropylene plunger rod.
Slovenian: Inhixa 4.000 i.e. (40 mg)/0,4 mL je 0,4 ml raztopine v: injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in z modrim polipropilenskim batom.
English: Very common: Thrombocytosi s β
Slovenian: Zelo pogosti: Trombocitoza β
English: In a second double-blind study, 262 patients without VTE disease and undergoing hip replacement surgery initially treated, while hospitalized, with enoxaparin sodium 4,000 IU (40 mg) subcutaneously were randomized to a post-discharge regimen of either enoxaparin sodium 4,000 IU (40 mg) (n=131) once a day subcutaneously or to placebo (n=131) for 3 weeks.
Slovenian: V drugi dvojno slepi študiji so 262 bolnikov brez venske trombembolične bolezni in z operativno zamenjavo kolka, ki so bili med hospitalizacijo uvodoma zdravljeni z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano, po odpustu za 3 tedne randomizirali na shemo z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano enkrat na dan (n = 131) ali na placebo (n = 131).
English: Subcutaneous injection technique
Slovenian: Postopek subkutanega injiciranja
English: One vial (3.0 mL) contains 30,000 IU (300 mg) enoxaparin sodium.
Slovenian: Ena viala (3,0 ml) vsebuje 30.000 i.e.e (300 mg) natrijevega enoksaparinata.
English: Enoxaparin sodium 4,000 IU (40 mg) once a day subcutaneously n (%)
Slovenian: Natrijev enoksaparinat 4.000 i.e. (40 mg) enkrat na dan subkutano n (%)
English: The following medicinal products may be administered with caution concomitantly with enoxaparin sodium: Other medicinal products affecting haemostasis such as: - Platelet aggregation inhibitors including acetylsalicylic acid used at antiaggregant dose (cardioprotection), clopidogrel, ticlopidine, and glycoprotein IIb/IIIa antagonists indicated in acute coronary syndrome due to the risk of bleeding, - Dextran 40, - Systemic glucocorticoids.
Slovenian: Naslednja zdravila se lahko previdno uporabijo sočasno z natrijevim enoksaparinatom: Druga zdravila, ki vplivajo na hemostazo, na primer: - zaviralci agregacije trombocitov, vključno z acetilsalicilno kislino v antiagregacijskih odmerkih (zaščita srca), klopidogrel, tiklopidin in antagonisti glikoproteina IIb/IIIa, ki so indicirani pri akutnem koronarnem sindromu, zaradi tveganja za krvavitve, - dekstran 40, - sistemski glukokortikoidi.
English: Switch between enoxaparin sodium and oral anticoagulants Switch between enoxaparin sodium and vitamin K antagonists (VKA) Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized Ratio (INR)] must be intensified to monitor the effect of VKA.
Slovenian: Prehod med natrijevim enoksaparinatom in peroralnimi antikoagulansi Prehod med natrijevim enoksaparinatom in antagonisti vitamina K (VKA - Vitamin K Antagonists) Za nadzor nad učinkom VKA je treba poostriti klinični nadzor in laboratorijske preiskave (protrombinski čas, izražen kot internacionalno normalizirano razmerje [INR]).